Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
2024年12月3日 - 9:30PM
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial
stage biotechnology company that aims to translate the genetics of
the adaptive immune system into clinical products to diagnose and
treat disease, announced that its next-generation sequencing
(NGS)-based clonoSEQ® test for measurable residual disease (MRD)
assessment will be included in more than 65 abstracts across eight
different types of blood cancer at the 66th Annual Meeting of the
American Society of Hematology (ASH) taking place December 7-10,
2024, in San Diego. Among these abstracts are a plenary session
presentation, a late-breaking abstract and 25 other oral
presentations.
“We are inspired to see clonoSEQ MRD testing featured in a
record-breaking number of studies at this year’s ASH Annual
Meeting,” said Susan Bobulsky, chief commercial officer, MRD,
Adaptive Biotechnologies. “The increasingly widespread use of
clonoSEQ as a highly sensitive test to support clinical
decision-making and as a primary endpoint in clinical trials
highlights its multi-faceted role in advancing precision medicine
in hematology.”
Multiple studies underscore the use of clonoSEQ as the standard
for demonstrating efficacy in pivotal clinical trials and highlight
advantages of leveraging the highest sensitivity in both clinical
trials and real-world practice across various blood cancers.
Notably, several practice-changing studies using MRD as a primary
endpoint in multiple myeloma (MM), mantle cell lymphoma (MCL), and
chronic lymphocytic leukemia (CLL), as well as studies using MRD
interventionally in acute lymphoblastic leukemia (ALL), MM, MCL,
and CLL, further validate its critical role in assessing deep
therapeutic responses and informing treatment decisions.
A complete list of the accepted abstracts featuring clonoSEQ is
available here.
About clonoSEQclonoSEQ is the first and only
FDA-cleared in vitro diagnostic (IVD) test to detect minimal
residual disease (MRD) in bone marrow from patients with multiple
myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and
blood or bone marrow from patients with chronic lymphocytic
leukemia (CLL). clonoSEQ testing for diffuse large B-cell lymphoma
(DLBCL) and mantle cell lymphoma (MCL) patients is currently
available for clinical use as a laboratory-developed test (LDT)
performed at Adaptive's CLIA-certified lab in Seattle, WA. clonoSEQ
is CE-marked under IVDR in the EU. For the approved intended use in
the EU under IVDR, please refer to the instructions for use,
available on request.
clonoSEQ leverages Adaptive Biotechnologies’ proprietary immune
medicine platform to identify and quantify specific DNA sequences
found in malignant cells, allowing clinicians to assess and monitor
MRD during and after treatment. The test provides standardized,
accurate, and sensitive measurement of MRD that allows physicians
to predict patient outcomes, assess response to treatment, inform
changes in therapy, monitor disease burden over time, and detect
potential relapse early. Clinical practice guidelines in
hematological malignancies recognize that MRD status is a reliable
indicator of clinical outcomes and response to therapy, and
clinical outcomes have been shown to be strongly associated with
MRD levels measured by the clonoSEQ in patients diagnosed with CLL,
MM, ALL and DLBCL.
For important information about the FDA-cleared uses of
clonoSEQ, including the full intended use, limitations, and
detailed performance characteristics, please
visit www.clonoSEQ.com/technical-summary.
About Adaptive BiotechnologiesAdaptive
Biotechnologies (“we” or “our”) is a commercial-stage biotechnology
company focused on harnessing the inherent biology of the adaptive
immune system to transform the diagnosis and treatment of disease.
We believe the adaptive immune system is nature’s most finely tuned
diagnostic and therapeutic for most diseases, but the inability to
decode it has prevented the medical community from fully leveraging
its capabilities. Our proprietary immune medicine platform reveals
and translates the massive genetics of the adaptive immune system
with scale, precision and speed. We apply our platform to partner
with biopharmaceutical companies, inform drug development, and
develop clinical diagnostics across our two business areas: Minimal
Residual Disease (MRD) and Immune Medicine. Our commercial products
and clinical pipeline enable the diagnosis, monitoring, and
treatment of diseases such as cancer, autoimmune disorders, and
infectious diseases. Our goal is to develop and commercialize
immune-driven clinical products tailored to each individual
patient.
Forward Looking Statements This press release
contains forward-looking statements that are based on management’s
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under “Risk Factors,” “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
ADAPTIVE INVESTORSKarina Calzadilla, Vice
President, Investor
Relations201-396-1687investors@adaptivebiotech.com
ADAPTIVE MEDIAErica Jones, Associate Director,
Corporate Communications206-279-2423media@adaptivebiotech.com
Adaptive Biotechnologies (NASDAQ:ADPT)
過去 株価チャート
から 11 2024 まで 12 2024
Adaptive Biotechnologies (NASDAQ:ADPT)
過去 株価チャート
から 12 2023 まで 12 2024